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Objectives   Retirement from paid work is a major life event facing increasingly large numbers of people in 
the coming years. We examined trajectories of mental health five years before and five years after old-age and 
disability retirement using data on purchases of psychotropic drugs.
Methods   The study included all employees from the City of Helsinki, Finland, retiring between 2000–2008 
due to old age (N=4456) or disability (N=2549). Purchases of psychotropic drugs were analyzed in 20 3-month 
intervals before and after retirement using graphical methods and growth curve models.
Results   Old-age retirement was unrelated to purchases of psychotropic drugs. Among disability retirees, psy-
chotropic medication tripled before retirement. The average increase was 0.95 [95% confidence interval (95% 
CI) 0.73–1.16] daily defined doses (DDD) 5–1.5 years before retirement; from 1.5 years until retirement it was 
5.68 DDD (95% CI 5.33–6.03) for each 3-month interval. After disability retirement, purchases of antidepres-
sants decreased on average by 0.40 DDD (95% CI 0.57–0.23) for each 3-month interval, those of hypnotics and 
sedatives increased by 0.30 DDD (95% CI 0.12–0.47), and no changes were seen for other psychotropic drugs. 
The changes before and after retirement were largest among those who retired due to mental disorders and those 
whose retirement had been granted as temporary.
Conclusions   While no overall decrease in psychotropic medication after retirement was observed, purchases 
of antidepressants decreased after disability retirement. Long-term trajectories suggest that disability retirement 
might be prevented if mental health problems were tackled more efficiently earlier in the pre-retirement period. 
Key terms   disability pension; health trajectory; medication; register data; register linkage; registry.
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Retirement from paid work is a major life event facing 
increasingly large numbers of people in the coming 
years in various European populations and the US (1). 
The transition to retirement has profound implications 
on an individual’s daily activities, social relationships, 
and material living conditions, and may have conse-
quences for health and well-being.
Health status before retirement and anticipation con-
cerning it after retirement are among the most important 
factors affecting the timing of retirement among ageing 
employees (2). Early retirement due to disability is 
common, and in many western countries the proportion 
of people who continue to work up to their statutory 
retirement age has been decreasing (3). Mental disor-
ders, particularly depression, have become increasingly 
prevalent reasons for disability retirement (3, 4).
The evidence on the possible effect of retirement on 
mental health is inconsistent (5–10). Furthermore, previ-
ous studies suffer from methodological drawbacks that 
make such an effect difficult to demonstrate. Most stud-
ies have been cross-sectional or two-wave panel studies 
comparing retirees to those continuing in employment, 
and selection out of employment due to poor health is 
likely to have a profound effect on the results. Studies 
using designs that can more effectively catch the effect 
of retirement on mental health and, that of mental health 
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on retirement, are few. Multi-wave panel surveys from 
the US Health and Retirement Study have reported an 
increase in mental health problems after retirement (6, 
11). French studies based on annually repeated surveys 
among predominantly old-age retirees found a reduction 
in depressive symptoms (12) and sleep disturbances 
(13) around the time of retirement. A Finnish study 
examining annual changes before and after the year of 
retirement found that, among old-age retirees and those 
retiring due to mental illnesses, antidepressant purchases 
diminished between the year before retirement and the 
year after retirement (14). Previous studies have mainly 
concentrated on post-retirement changes in mental 
health. Furthermore, most of them suffer from sizeable 
survey non-participation and have not made a clear 
distinction between statutory retirement at a predefined 
retirement age and early retirement due to disability.
We examined trajectories of mental health before and 
after retirement using data on purchases of psychotropic 
drugs. The availability of longitudinal register-based 
data provides an excellent opportunity to analyze such 
trajectories over a period extending from 5 years before 
to 5 years after retirement in a large sample of both old-
age and disability retirees. We separately examined dif-
ferent types of psychotropic drugs and disability retire-
ment types. Any change in medication after retirement 
is indicative of an effect of retirement on mental health 
whereas a change before retirement provides evidence of 
selection into retirement due to mental health problems.
Methods
Data sources
The study population consisted of all employees from 
the City of Helsinki who were working on 1 January 
2000 and retired by the end of 2008 due to old age 
(N=4456) or disability (N=2549). The City of Helsinki 
is the largest single employer in Finland, with nearly 
40 000 employees at the beginning of 2000. The mean 
age of the employees was 41.7 years. Main employ-
ment sectors include social and healthcare, education, 
public transportation, cultural services, environmental 
and technical maintenance, and public administration.
In Finland, a flexible retirement age of 63–68 years 
was adopted in the beginning of 2005 (15). It is thus 
possible to retire at the age of 63, but working thereafter 
progressively improves one’s pension. Older employees 
may still have a lower retirement age based on earlier 
agreements, which are more common in the public 
sector. For those <63 years, a disability pension can be 
granted if the employee’s work ability is reduced due to 
illness, handicap, or injury for a continuous period of 
≥1 year. Most disability pensions are permanent but a 
temporary disability pension can be granted if recovery 
is anticipated. A partial disability pension can be granted 
if the employee can cope with part-time work or lighter 
tasks than earlier.
Data on retirement events were obtained from a 
national register of the Finnish Centre for Pensions. 
These data included the date of retirement, retirement 
type, principal diagnosis for disability retirement, as 
well as the date of death if it had occurred after retire-
ment. The data included 4456 old-age retirees [mean age 
at retirement 61.8, standard deviation (SD) 2.0, years] 
and 2549 disability retirees [mean age at retirement 
53.5 (SD 7.5) years]. We separately examined those 
who retired due to mental and behavioral disorders 
[International Classification of Diseases (ICD-10) codes 
F00–F99, 908 retirement events] and due to other causes 
(1641 retirement events). We also separated permanent 
disability retirements (1607 events), temporary dis-
ability retirements (467 events), and partial disability 
retirements (475 events).           
Data on purchases of psychotropic drugs from the 
beginning of 1995 until the end of 2009 were derived 
from the Social Insurance Institution of Finland’s reg-
ister. Physicians write all prescriptions and information 
on all prescribed drugs purchased from any pharmacy 
in the country is forwarded to this register as part of 
the national drug reimbursement scheme. The data 
include the date of the purchase, the type of medication 
[classified according to the World Health Organization 
Anatomical Therapeutic Chemical (ATC) classification], 
and the amount of medication in defined daily doses 
(DDD) (16). We extracted all psycholeptics (ATC codes 
N05) and psychoanaleptics (N06), except medication 
for dementia (N06D). We divided the drugs into three 
large groups, consisting of antidepressants (N06A), 
hypnotics and sedatives (N05B and N05C), and other 
psychotropic drugs.
Linkage of the data sources was done using unique 
personal identification numbers assigned to all Finnish 
residents. The ethics committees at the University of 
Helsinki’s Department of Public Health and the City of 
Helsinki Health Authorities approved the study.
Study design
For each of the 7005 retirees, the date of retirement 
was taken as the reference time point, and the time 
before and after retirement was divided into 3-month 
intervals. For all retirees, 20 3-month intervals were 
formed for both before and after retirement. Complete 
data on psychotropic medication before retirement were 
available for all retirees. After retirement, complete 
data were available for those who had retired before 1 
November 2004. For those who retired after that date, 
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the data became progressively sparser the later the 
retirement occurred. Furthermore, retirees who died 
during the follow-up (N=148) were censored from the 
next interval after which the death had occurred. In the 
last interval after retirement, data on medication was 
available for 3421 (49%) of the retirees. Sensitivity 
analyses (supplementary figure A: http://www.sjweh.fi/
data_repository.php) made among those with complete 
data after retirement showed that the attrition had no 
influence on the results.
Statistical analysis
We graphically presented the mean amount of drugs 
purchased over the 3-month intervals [DDD with 95% 
confidence intervals (95% CI)] centered around retire-
ment. Growth curve models were used to test statistical 
significance of the changes in psychotropic medica-
tion before and after disability retirement (Wald test 
for linear hypotheses) and to control for the effects of 
covariates (17). Since growth curve models are formally 
described as multilevel random-coefficient models with 
repeated measurements nested within individuals, they 
account for the within-person clustering of drug pur-
chases (18). For these analyses, the observation time 
before disability retirement was divided into two broad 
time bands based on visual inspection of the data: 5–1.5 
years before retirement and 1.5–0 years before retire-
ment. This division also roughly corresponds to the 
Finnish retirement system where the disability retire-
ment application process typically takes about one year. 
Interactions with gender and socioeconomic position 
(manual versus non-manual) were included to exam-
ine whether the trajectories were different for these 
variables. Separate analyses were conducted for the 
retirement type, the type of medication, and disability 
diagnosis. We adjusted for retirement age and time of 
retirement in all models. All analyses were conducted 
using STATA 11 (StataCorp, College Station, TX, USA).
Results
The purchases of psychotropic drugs increased before 
disability retirement (figure 1, see also table 1). There 
was a long moderate increase that accelerated approxi-
mately 1.5 years before retirement (P for quadratic term 
<0.001). While the average amount of psychotropic 
medication 5 years before disability retirement was 
about 25 DDD over a 3-month interval, during the 
3-month interval immediately before the retirement it 
was nearly 70 DDD. Two and half years after disability 
retirement, the average purchase of psychotropic drugs 
was 60 DDD per person during a 3-month interval, 
remaining at the same level thereafter (P for curvilinear 
change after retirement <0.001). Among those retiring 
due to old age, purchases amounted to about 10 DDD 
per each 3-month interval, with a slow and constant 
increase towards the later intervals, but no change at the 
time of the retirement. 
Figure 2 shows purchases of psychotropic drugs 
before and after disability retirement by medication 
type (see also table 1). Before disability retirement, the 
purchases of antidepressants increased more rapidly 
than those of other psychotropic drugs. This concerned 
both the long-term increase and the more rapid increase 
1.5 years before retirement. However, the purchases of 
hypnotics and sedatives as well as other psychotropic 
drugs also increased before retirement, with the increase 
accelerating closer to retirement (P for quadratic term 
<0.001). After retirement, the trajectories differed 
by medication type: the purchases of antidepressants 
decreased, those of hypnotics and sedatives continued 
to increase, and no changes were observed in other 
psychotropic drugs.
Among those who retired due to mental and behav-
ioral disorders, the increase in psychotropic medication 
before retirement was very steep, but steadily decreased 
after retirement (figure 3, see also table 1). Among those 
who retired due to other causes, psychotropic medication 
was considerably lower. However, psychotropic medica-
tion nearly tripled during the five years before retirement 
(P for quadratic term <0.001).
The purchases of psychotropic drugs increased 
before disability retirement irrespective of the disabil-
ity retirement type (figure 4, see also table 1). However, 
the increase was particularly steep among those with 
temporary disability retirement. In this group, the pur-
chases also decreased most after the retirement (P for 
curvilinear change <0.001), whereas in the other groups, 
there was no change after retirement.
Table 1 presents the results from the growth curve 
models among disability retirees. The average increase 
in psychotropic medication 5–1.5 years before dis-
ability retirement was 0.95 DDD (95% CI 0.73–1.16) 
per each 3-month interval. From 1.5– 0 years before 
disability retirement, the increase was 5.68 DDD (95% 
CI 5.33–6.03) per each 3-month interval. The decrease 
after disability retirement was not statistically significant 
(P=0.62). However, if the time after disability retirement 
were divided into two time bands, psychotropic medica-
tion would decrease during the first 2.5 years (P<0.001) 
and slightly increase thereafter (P<0.001).
The results were similar among women and men 
(table 1). Larger increases in psychotropic medication 
before disability retirement was seen in the non-manual 
socioeconomic group (P for interaction <0.001) and, 
after retirement, the trends diverged (P=0.04). The 
increase in psychotropic medication before disability 
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Figure 1. Purchases of psychotropic drugs before and after retirement, by retirement type. Each retiree was followed-up for a period from five 
years before retirement until five years after retirement. The vertical line indicates the time of the retirement.
Figure 2. Purchases of psychotropic drugs before and after disability retirement, by medication type. Each retiree was followed-up for a period 
from five years before retirement until five years after retirement. The vertical line indicates the time of the retirement.
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Table 1. Average change in the purchases of psychotropic drugs in daily defined doses (DDD) per one 3-month interval with 95% con-
fidence intervals (95% CI) among disability retirees before and after retirement.
Average change (DDD) in purchased psychotropic drugs
5–1.5 years before retirement 1.5–0 years before retirement After retirement  (0–5 years)
Mean 95% CI Mean 95% CI Mean  95% CI
Overall a 0.95  0.73–1.16 5.68 5.33–6.03  -0.07 -0.35– 0.21
By gender a
Male 0.64  0.16–1.13 5.92 5.20–6.63  -0.05 -0.74– 0.65
Female 1.02  0.78–1.26 5.61 5.21–6.01  -0.08 -0.38– 0.22
By social class b
Manual 0.41  0.08–0.74 4.04 3.53–4.56  0.42  0.01– 0.84
Non-manual 1.15  0.88–1.42 6.29 5.84–6.73  -0.25  -0.61– 0.10
By medicine type c
Antidepressants 0.63  0.49–0.77 3.95 3.71–4.20  -0.40  -0.57–-0.23
Hypnotics & sedatives 0.28  0.16–0.41 1.08 0.87–1.28  0.30  0.12– 0.47
Other psychotropic drugs 0.04  -0.01–0.08 0.65 0.57–0.72  0.04  -0.04– 0.12
By reason for disability retirement c
Mental and behavioural disorders 1.90  1.41–2.40 12.4 11.6–13.2 -0.92 -1.58–-0.26
Other diseases 0.42  0.26–0.58 1.95 1.67–2.23  0.41  0.19– 0.62
By disability retirement type c
Permanent 0.95 0.69–1.22 4.83 4.40–5.27 -0.12  -0.45–0.22
Temporary 1.23 0.65–1.80 10.37 9.43–11.32 -0.21  -1.15–0.72
Partial 0.65 0.21–1.09 3.94 3.23–4.65 0.27  -0.21–0.75
a Adjusted for retirement year and age at retirement.
b Adjusted for retirement year, age at retirement, and gender. 
c Adjusted for retirement year, age at retirement, gender, and social class.
Figure 3. Purchases of psychotropic drugs before and after disability retirement, by retirement diagnosis. Each retiree was followed-up for a period 
from five years before retirement until five years after retirement. The vertical line indicates the time of the retirement.
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retirement was mainly driven by antidepressants. For 
antidepressants, there was a statistically significant 
decrease after retirement (P<0.001), whereas the pur-
chases of hypnotics and sedatives increased (P =0.001), 
and no change was observed in other psychotropic drugs 
(P=0.32). These analyses also substantiate the huge pre-
retirement increase in psychotropic medication among 
those who retired due to mental disorders and those with 
temporary disability retirement (P <0.001) and the more 
moderate decrease thereafter.
Discussion
This study showed that retirement is differently asso-
ciated with psychotropic medication depending on 
whether it is statutory old-age retirement or disability 
retirement. Old-age retirement was unrelated to pur-
chases of psychotropic drugs. Among disability retirees, 
psychotropic medication increased before retirement. 
However, changes after disability retirement depended 
on medication type. While the purchases of antide-
pressants decreased, those of hypnotics and sedatives 
increased, and no changes were seen in other psycho-
tropic drugs. The changes were largest among those 
who retired due to mental disorders and those with 
temporary disability retirement, but notable increases 
were seen also in the other groups during the 5 years 
preceding retirement. The results were similar among 
women and men, but bigger changes before and after 
disability retirement were observed among non-manual 
employees.
Interpretation of the findings
Our most striking finding was the steep increase in 
the purchases of psychotropic drugs before disability 
retirement. Among disability retirees, the level of psy-
chotropic medication was high already 5 years before 
the retirement, and approximately 1.5 years before 
the retirement there was an accelerating increase. This 
increase is consistent with selection into retirement 
of those with worsening mental health. Nevertheless, 
there are also other reasons that could contribute to 
the increase in medication before disability retirement. 
Disability retirement is normally preceded by a period 
of 300 sickness absence days when the possibilities for 
medical and vocational rehabilitation are examined (4). 
Psychotropic medication could be increased during this 
period of intensified treatment and rehabilitation. The 
finding that the preretirement increase in medication was 
largest among those with temporary disability retirement 
supports this interpretation, as such individuals meet the 
Figure 4. Purchases of psychotropic drugs before and after retirement, by disability retirement type. Each retiree was followed-up for a period 
from five years before retirement until five years after retirement. The vertical line indicates the time of the retirement.
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most active rehabilitation measures. Furthermore, the 
retirement process itself can be strenuous and exhaust-
ing leading to increased use of psychotropic medication.
Since those who retired due to disability had elevated 
use of psychotropic medication already 5 years before 
their retirement, our findings also suggest that for most 
employees, mental health problems do not lead to a 
rapid retirement. Thus disability retirement events might 
be prevented if mental health problems were tackled at 
an earlier stage. A British study showed that those who 
eventually retired due to health problems had poorer 
mental functioning already in their 40s (19). The long-
term trajectories before disability retirement imply that 
people with some history of mental health problems 
may keep working if their situation is not aggravated. 
A Finnish study showed that even though the use of 
antidepressants has increased and the clinical practice 
guidelines for depression have been improved, a large 
proportion of those retiring due to mental health prob-
lems are still sub-optimally treated (20). Unfortunately, 
we are not aware of the measures of rehabilitation, 
occupational health precautions or adaptation of work 
tasks that may have been taken in order to facilitate 
staying at work.
Overall, no changes were seen in psychotropic 
medication after disability retirement but the develop-
ment differed by medication type. The purchases of 
antidepressants decreased. This is consistent with the 
hypothesis that relieving work-related stress may lead to 
improved mental health after retirement (21). Moreover, 
with retirement, one’s life situation profoundly changes, 
and – if managing everyday life becomes easier – symp-
toms of illness may alleviate and become less disturbing. 
After 2.5 years, the post-retirement decrease leveled off 
and antidepressant medication remained at a consider-
ably higher level than it had been prior to retirement. 
The leveling off may reflect adaptation to new cir-
cumstances over time as people reassess their changed 
life situation and get accustomed to their new roles 
and everyday routines (22). The development is also 
consistent with the usual course of illness for depres-
sive disorders that includes remission with successful 
treatment but reoccurrence, if there is no maintenance 
treatment, within some years (23). Such course may 
have taken place during the follow-up after intensive 
treatment preceding disability retirement. 
In contrast to antidepressants, the purchases of hyp-
notics and sedatives continued to increase after disability 
retirement although at a slightly slower pace than before. 
This finding is somewhat unexpected, as similar factors 
that explained the decrease in antidepressants could be 
assumed to hold for hypnotics and sedatives as well. 
Furthermore, sleep problems such as feeling tired after 
non-refreshing sleep (24) may relate to waking up early 
in the morning, which could be expected to be less dis-
turbing after retirement, if not depressed. One possible 
reason for the continuing increase is that hypnotics and 
sedatives tend to cause tolerance and subsequent depen-
dence that are likely to impede cessation of medication 
and result in increasing dosage (25).
After disability retirement, the purchases of other 
psychotropic drugs remained at a constant level. These 
drugs are normally used to treat more severe mental 
disorders (ie, with psychotic symptoms) than those in 
the other two classes. It is thus reasonable that once such 
problems emerge, they do not get resolved so easily. Just 
before retirement, the purchases of other psychotropic 
drugs increased to a whole new level, suggesting that 
the early retirement system is, at least to some degree, 
able to recognize disabling health problems. According 
to clinical practice guidelines (26), these drugs are an 
option for augmenting antidepressant medication that 
might also partly explain the increase.
The decrease in psychotropic medication following 
retirement was restricted to those retiring due to mental 
disorders and those with temporary disability retire-
ment. These results also agree with the finding that the 
post-retirement decrease was seen for antidepressants 
but not other drugs. Since depression is a major cause 
for disability retirement due to mental disorders (4, 15), 
antidepressants are likely to be predominant among 
those who retire due to mental disorders whereas hyp-
notics and sedatives may be more common among those 
retiring due to other causes. Furthermore, since disabil-
ity retirement due to mental disorders is often granted 
as temporary, it is reasonable that the changes were 
strongest in this group. The post-retirement decrease in 
medication may also reflect successful rehabilitation as 
roughly half of those with temporary disability retire-
ment return to the labor force while, for the other half, 
retirement becomes permanent. 
Overall, the findings on pre- and post-retirement 
changes are partly similar to and different from those 
seen in previous studies. A Norwegian study linking the 
date of retirement to a previously made questionnaire 
survey found that depression and anxiety was most 
common among those who responded to the study just 
before or soon after their disability retirement (27). A 
French study found that depressive symptoms decreased 
markedly in the years of old-age retirement, breaking 
the pattern of a slow, long-term increase (12). Another 
study including also disability retirees found that sleep 
disturbances followed a similar pattern (13). A Finnish 
study found a decreasing use of antidepressants after 
retirement among those retiring due to mental illnesses 
but not among those retiring due to physical illnesses 
(14). A decrease was also found among old-age retirees 
from the year preceding retirement to the year follow-
ing retirement, after adjusting for retirement age and 
calendar year. This is different from our study showing 
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a constant increase in the purchases of all psychotropic 
drugs among old-age retirees. The increase was mainly 
related to hypnotics and sedatives, but there was no clear 
change in the purchases of antidepressants at the time 
of the retirement (supplementary figure F: http://www.
sjweh.fi/data_repository.php). 
Strengths and weaknesses of the study
The strengths of this study include a large study popu-
lation and reliable register-based data on retirement 
and drug purchases. However, a limitation is that the 
data were derived from a single employer, the City of 
Helsinki. In the Finnish municipalities, occupational 
structures and typical work tasks differ from those of the 
private sector and the central government. There are also 
slight differences in the policy and practices of grant-
ing disability retirement. Therefore, generalization of 
these results to the total workforce should be made with 
caution. Nevertheless, old-age and disability retirement 
ages in this cohort roughly correspond to the national 
averages (15) and the level of psychotropic medication 
was approximately the same as that previously found 
in nationwide surveys (28). In these data, information 
was not available on the clinical indication for which 
the psychotropic medication was prescribed. Given that 
depressive and anxiety disorders have high co-morbidity 
(29) and antidepressants can also be used in the treatment 
of anxiety disorders (30), different mental health problem 
cannot be exclusively distinguished using data on medi-
cation. Furthermore, the drugs examined here can also 
be used for other purposes, such as treating chronic pain, 
but this is relatively rare when considering the overall 
use of psychotropic medication. The analyses presented 
examined the amount of medication measured in DDD. 
Sensitivity analyses were conducted using a dichotomous 
measure of having redeemed at least one purchase during 
the 3-month interval, and the results remained basically 
identical (supplementary figures B–E in the Appendix: 
http://www.sjweh.fi/data_repository.php).
Concluding remarks
In this study based on closely-spaced repeated measure-
ments on psychotropic medication extending from 5 years 
before to 5 years after retirement, we found no overall 
decrease in medication after retirement. Yet the purchases 
of antidepressants decreased after disability retirement, 
suggesting a possible beneficial effect of retirement on 
mental health. Post-retirement decrease was also seen 
among those who retired due to mental disorders and 
those with temporary disability retirement. In addition to 
effects of changes in life circumstances, this may reflect 
a wearing off of the intensive pre-retirement treatment 
or successful return to work after temporary retirement.
We also found that purchases of psychotropic drugs 
increased dramatically before disability retirement. 
While this suggests that the disability retirement proce-
dure may work well in identifying those with worsening 
mental health, the long-term trajectories in this observa-
tional study also suggest that disability retirement might 
events be prevented if mental health problems were 
tackled more efficiently earlier in the pre-retirement 
period. Since preventing early retirement plays a key 
role in lengthening work careers, tackling mental health 
problems before they are aggravated should be of pri-
mary concern for political decision-makers and other 
actors striving to reach this goal.
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